The Scenesse implant releases afamelanotide continuously over 60 days, so pigmentation accumulates gradually most patients report visible darkening by week 23
Exendin-4 and GLP-1 are 50% identical, and exendin-4 is a full agonist with similar affinity and potency for the GLP-1 receptor
"PTEN identified as important risk factor of chronic obstructive pulmonary disease"
Protease-antiprotease balance is extremely disrupted in severe bronchiectasis, as shown in proteomic studies of sputum from patients with bronchiectasis that demonstrated that both elevated NSPs and reduced secretory leukocyte protease inhibitor levels were associated with disease severity (117, 118)
"Not FDA-approved" just means the FDA hasn't reviewed or signed off on its safety, efficacy, dosing, or manufacturing for people
BPC-157 remains on the 2025 Prohibited List